Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/496
A61K-031/501
A61K-031/34
출원번호
US-0540577
(2003-12-25)
등록번호
US-8759350
(2014-06-24)
우선권정보
JP-2002-379003 (2002-12-27)
국제출원번호
PCT/JP03/16724
(2003-12-25)
§371/§102 date
20051216
(20051216)
국제공개번호
WO2004/060374
(2004-07-22)
발명자
/ 주소
Kikuchi, Tetsuro
Iwamoto, Taro
Hirose, Tsuyoshi
출원인 / 주소
Otsuka Pharmaceutical Co., Ltd.
대리인 / 주소
Sughrue Mion, PLLC
인용정보
피인용 횟수 :
2인용 특허 :
23
초록▼
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
대표청구항▼
1. A pharmaceutical composition comprising (a) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from citalopram, escitalopram and salts thereof. 2. A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibito
1. A pharmaceutical composition comprising (a) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from citalopram, escitalopram and salts thereof. 2. A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from citalopram and salts thereof. 3. The pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and a salt thereof. 4. The composition of any one of claims 1, 2 and 3 wherein aripiprazole is anhydrous aripiprazole crystals B. 5. The composition of any one of claims 1, 2 and 3 further comprising at least one pharmaceutically acceptable carrier. 6. The composition of any one of claims 1, 2 and 3 being useful for the treatment of depression or major depressive disorder. 7. The composition of any one of claims 1, 2 and 3 being useful for the treatment of major depressive disorder dementia with depressive symptoms. 8. The composition of any one of claims 1, 2 and 3 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury. 9. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition which comprise(s) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of citalopram, escitalopram and salts thereof. 10. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of citalopram, and salts thereof. 11. The method of a treating mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof. 12. The method of any one of claims 9 to 11, wherein aripiprazole is anhydrous aripiprazole crystals B. 13. The method of any one claims 9 to 11, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier. 14. The method of any one claims 9 to 11, being useful for the treatment of depression of major depressive disorder. 15. The method of any one of claims 9 to 11, being useful for the treatment of major depressive disorder or dementia with depressive symptoms. 16. The method of any one of claims 9 to 11, being useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury. 17. The composition of claim 5, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of fillers, extenders, binders, moisturizers, disintegrants, surfactants and lubricants. 18. The composition of claim 1, wherein the amount of (a) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from citalopram, escitalopram and salts thereof is 1 to 70 parts by weight of the total composition.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (23)
Yelle William E., 2-hydroxymethylolanzapine compositions and methods.
Blum Kenneth (San Antonio TX) Noble E. P. (Los Angeles CA) Sheridan P. J. (San Antonio TX), Allelic association of the human dopamine(D2) receptor gene in compulsive disorders.
Eswara Amruta R. ; Muni Neal ; Schneider F. Howard ; Mione Peter J., Methods and articles of manufacture for nicotine cessation and monitoring nicotine use.
Broekkamp Christophorus Louis Eduard,NLX ; Berendsen Hermanus Henricus Gerardus,NLX ; Pinder Roger Martin,NLX, Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.